QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
NYSE:TAK

Takeda Pharmaceutical - TAK Stock Forecast, Price & News

$16.36
+0.14 (+0.86%)
(As of 03/24/2023 04:29 PM ET)
Add
Compare
Today's Range
$16.19
▼
$16.37
50-Day Range
$15.28
▼
$16.44
52-Week Range
$12.28
▼
$16.58
Volume
1.42 million shs
Average Volume
2.78 million shs
Market Capitalization
$51.77 billion
P/E Ratio
24.79
Dividend Yield
3.30%
Price Target
$22.00

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
34.5% Upside
$22.00 Price Target
Short Interest
Healthy
0.16% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.20mentions of Takeda Pharmaceutical in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

205th out of 989 stocks

Pharmaceutical Preparations Industry

86th out of 480 stocks

See Top Rated MarketRank™ Stocks Here

TAK stock logo

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

March 21, 2023 | marketbeat.com
Price Growth & Yield: For That Magical Combo, Leave the U.S. (TAK)
Three foreign stocks, Takeda Pharmaceutical, United Microelectronics, and Coca-Cola FEMSA are showing that magical combination of growth and yield.
March 24, 2023 | marketwatch.com
Erosive Esophagitis (EE) Market Trends, Industry Demand and Scope, Top Players Analysis, Forecast 2023 - 2031
March 24, 2023 | Weiss Ratings (Ad)
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
March 24, 2023 | marketwatch.com
2023-2028 Pharmaceutical Market: Forecasting Growth and Trends
March 24, 2023 | marketwatch.com
Dry Eye Disease (DED) Market by 2031
March 24, 2023 | seekingalpha.com
Takeda to invest ¥100B for new plasma-derived drugs facility in Japan
March 23, 2023 | marketwatch.com
Drug for Ulcerative Colitis Market Size 2023 Global Industry Development Analysis by Manufacturers Profiles and Forecast till 2026
March 22, 2023 | marketwatch.com
Antibody Drug Conjugate Market Growth and Forecast till 2031
March 24, 2023 | Weiss Ratings (Ad)
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
March 21, 2023 | uk.finance.yahoo.com
Global Cell Therapy Market Report 2023: Major Players Include Fibrocell Science, JCR Pharmaceuticals, PHARMICELL and Osiris Therapeutics
March 21, 2023 | uk.finance.yahoo.com
Global Generic Pharmaceuticals Market Report 2023: Sector to Reach $682.9 Billion by 2030 at a CAGR of 8.3%
March 20, 2023 | marketwatch.com
Constipation Market Top Players and Forecast till 2028
March 20, 2023 | marketwatch.com
Penicillin Market Size and Forecast till 2028
March 20, 2023 | seekingalpha.com
Takeda hits main goals in mid-stage trial for plaque psoriasis therapy
March 19, 2023 | americanbankingnews.com
Takeda Pharmaceutical (NYSE:TAK) Lifted to "Buy" at Bank of America
March 18, 2023 | bloomberg.com
Takeda’s $4 Billion Psoriasis Pill Helped Clear Skin in Mid-Stage Study
March 15, 2023 | marketwatch.com
Hemorrhoid Treatment Market Research Report 2023-2029 with Top Countries Data
March 15, 2023 | marketwatch.com
2023, Insomnia Treatment Drugs Market to Eyewitness Massive Growth by 2030
March 15, 2023 | marketwatch.com
Digestive Distress Treatment Market Research Report (2023-2030) | Gain a Competitive Edge with Top Key Players
March 14, 2023 | marketwatch.com
Zika Virus Therapeutics Market Size, Growth | Soaring Demand | 2023 - 2029
March 14, 2023 | marketwatch.com
Global Antidiabetics Market Segment and Insights 2023 to 2027: Analysis by Sales and Profit Projections
March 14, 2023 | marketwatch.com
Dengue Vaccine Market to Grow Exponentially Due to Rising Demand
March 13, 2023 | marketwatch.com
2029 Forecast Circadian Rhythm Sleep Disorder Market 2023 by Growth Rate, Sparked Innovation with Top Players
March 13, 2023 | benzinga.com
Cell Therapy Market Size & Share to Surpass USD 16.1 Billion by 2028 | Vantage Market Research
March 13, 2023 | marketwatch.com
Prucalopride Succinate Market Application, Product, Sales and Forecast 2023-2028
March 13, 2023 | marketwatch.com
Stress Management Supplements Market [Latest Report] Review Report 2023 Alongside Insights, Figures till 2029
March 13, 2023 | finance.yahoo.com
GHIT Fund Announces New Investments: A Total of Approximately 260 Million Yen in Shionogi, Takeda Pharmaceutical for New Malaria Drug Development
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Last Earnings
2/02/2023
Today
3/24/2023
Fiscal Year End
3/31/2023
Next Earnings (Estimated)
5/10/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:TAK
CUSIP
N/A
CIK
1395064
Web
www.takeda.com
Phone
(166) 204-2111
Fax
813-3278-2268
Employees
47,347
Year Founded
1781

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+35.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.66
Trailing P/E Ratio
24.62
Forward P/E Ratio
7.52
P/E Growth
N/A
Net Income
$2.05 billion
Net Margins
6.84%
Pretax Margin
6.23%
Return on Equity
12.43%
Return on Assets
5.58%

Debt

Debt-to-Equity Ratio
0.63
Current Ratio
1.16
Quick Ratio
0.75

Sales & Book Value

Annual Sales
$31.79 billion
Price / Sales
1.62
Cash Flow
$3.55 per share
Price / Cash Flow
4.58
Book Value
$16.31 per share
Price / Book
1.00

Miscellaneous

Outstanding Shares
3,164,590,000
Free Float
3,163,325,000
Market Cap
$51.42 billion
Optionable
Optionable
Beta
0.64

Social Links


Key Executives

  • Christophe Weber
    President, CEO & Representative Director
  • Constantine Saroukos
    Chief Financial Officer & Director
  • Andrew S. Plump
    Director, President-Research & Development
  • Michael E. Mendelsohn
    Chief Medical & Scientific Officer
  • Norimasa Takeda
    Chief Accounting Officer & Corporate Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings or view top-rated stocks.

What is Takeda Pharmaceutical's stock price forecast for 2023?

4 brokers have issued 12-month price targets for Takeda Pharmaceutical's stock. Their TAK share price forecasts range from $20.00 to $24.00. On average, they predict the company's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 35.4% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2023?

Takeda Pharmaceutical's stock was trading at $15.60 at the beginning of 2023. Since then, TAK shares have increased by 4.2% and is now trading at $16.25.
View the best growth stocks for 2023 here.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our TAK earnings forecast.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) issued its quarterly earnings results on Thursday, February, 2nd. The company reported $0.46 earnings per share for the quarter. The company earned $8.40 billion during the quarter. Takeda Pharmaceutical had a net margin of 6.84% and a trailing twelve-month return on equity of 12.43%.

What ETFs hold Takeda Pharmaceutical's stock?

ETFs with the largest weight of Takeda Pharmaceutical (NYSE:TAK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), First Trust International IPO ETF (FPXI), Pacer Developed Markets International Cash Cows 100 ETF (ICOW), B.A.D. Etf (BAD), Pacer Global Cash Cows Dividend ETF (GCOW), ETFMG Treatments Testing and Advancements ETF (GERM) and Invesco Zacks Multi-Asset Income ETF (CVY).Pacer Trendpilot International ETF (PTIN).

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.54 per share and currently has a dividend yield of 3.29%. The dividend payout ratio is 81.82%. Payout ratios above 75% are not desirable because they may not be sustainable.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2022 earnings guidance on Thursday, February, 2nd. The company provided earnings per share guidance of $3.72-$3.72 for the period. The company issued revenue guidance of $27.84 billion-$27.84 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Morgan Stanley (0.15%), Mondrian Investment Partners LTD (0.14%), Clal Insurance Enterprises Holdings Ltd (0.14%), Arrowstreet Capital Limited Partnership (0.13%), Macquarie Group Ltd. (0.12%) and Renaissance Technologies LLC (0.09%).

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $16.25.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $51.42 billion and generates $31.79 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.66 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

The company employs 47,347 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 3/24/2023 by MarketBeat.com Staff